作者
Frank B Cortazar, Zoe A Kibbelaar, Ilya G Glezerman, Ala Abudayyeh, Omar Mamlouk, Shveta S Motwani, Naoka Murakami, Sandra M Herrmann, Sandhya Manohar, Anushree C Shirali, Abhijat Kitchlu, Shayan Shirazian, Amer Assal, Anitha Vijayan, Amanda DeMauro Renaghan, David I Ortiz-Melo, Sunil Rangarajan, A Bilal Malik, Jonathan J Hogan, Alex R Dinh, Daniel Sanghoon Shin, Kristen A Marrone, Zain Mithani, Douglas B Johnson, Afrooz Hosseini, Deekchha Uprety, Shreyak Sharma, Shruti Gupta, Kerry L Reynolds, Meghan E Sise, David E Leaf
发表日期
2020/2/1
期刊
Journal of the American Society of Nephrology
卷号
31
期号
2
页码范围
435-446
出版商
LWW
简介
Background
Despite increasing recognition of the importance of immune checkpoint inhibitor–associated AKI, data on this complication of immunotherapy are sparse.
Methods
We conducted a multicenter study of 138 patients with immune checkpoint inhibitor–associated AKI, defined as a≥ 2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune checkpoint inhibitor. We also collected data on 276 control patients who received these drugs but did not develop AKI.
Results
Lower baseline eGFR, proton pump inhibitor use, and combination immune checkpoint inhibitor therapy were each independently associated with an increased risk of immune checkpoint inhibitor–associated AKI. Median (interquartile range) time from immune checkpoint inhibitor initiation to AKI was 14 (6–37) weeks. Most patients had subnephrotic proteinuria, and approximately half had pyuria. Extrarenal …
学术搜索中的文章
FB Cortazar, ZA Kibbelaar, IG Glezerman… - Journal of the American Society of Nephrology, 2020